<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695262</url>
  </required_header>
  <id_info>
    <org_study_id>1800</org_study_id>
    <nct_id>NCT04695262</nct_id>
  </id_info>
  <brief_title>EUS-Elastography and Contrast-Enhanced EUS Diagnostic Accuracy in the Differential Diagnosis of Subepithelial Gastrointestinal Tumors</brief_title>
  <acronym>SUNNYDAY</acronym>
  <official_title>EUS-Elastography and Contrast-Enhanced EUS Diagnostic Accuracy in the Differential Diagnosis of Subepithelial Gastrointestinal Tumors: a Multicenter Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The differentiation among the Gastrointestinal Subepithelial Tumors (SETs) represents a&#xD;
      clinical challenge. Endoscopic Ultrasound (EUS) alone may be ineffective in differentiating&#xD;
      SETs subtypes, and tissue sampling of these lesions may be technically difficult. EUS&#xD;
      Elastography (EUS-E) has been applied to many gastrointestinal diseases, providing a&#xD;
      qualitative/semi-quantitative stiffness analysis, but only few studies have examined the role&#xD;
      of EUS-E in the diagnosis of SETs. In addition, the use of contrast agents has improved the&#xD;
      diagnostic performance of the EUS, especially in the differentiation between GISTs and other&#xD;
      gastrointestinal SETs.&#xD;
&#xD;
      The aim of the study is to examine the performance of EUS-E and Contrast Enhanced-EUS&#xD;
      (CE-EUS) in distinguishing among different gastrointestinal SETs subtypes. EUS patterns of&#xD;
      different techniques will be compared to the final diagnosis gained by the analysis of&#xD;
      histopatological specimens (surgical resection or EUS-FNB) or imaging/clinical follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>EUS-E accuracy in terms of qualitative and quantitative elastography</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluation of EUS-E accuracy (qualitative and quantitative elastography) and contrast enhanced endoscopic ultrasound (CE-EUS) in the diagnosis of SETs.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Gastrointestinal Subepithelial Tumors</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EUS-FNB</intervention_name>
    <description>Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with subepithelial gastrointestinal tumors&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with GI SETs scheduled for EUS-FNB&#xD;
&#xD;
          -  Patients with age &gt; 18 but &lt;85 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with GI SETs &lt;15mm&#xD;
&#xD;
          -  severe coagulopathy defined as abnormal prothrombin time (PT) or partial&#xD;
             thromboplastin time (PTT) that does not normalize after administration of fresh frozen&#xD;
             plasma&#xD;
&#xD;
          -  severe cardiopulmonary diseases and severe chronic kidney disease defined as&#xD;
             glomerular filtration rate (GFR) &lt; 15 ml/min&#xD;
&#xD;
          -  known allergic disposition to SonoVueÂ®&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Silvia Carrara, MD</last_name>
    <phone>0039-02-82247388</phone>
    <email>silvia.carrara@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandro Repici, MD</last_name>
    <phone>0039-02-82247493</phone>
    <email>alessandro.repici@hunimed.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Anderloni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Di Leo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta Maselli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Fugazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessia Galtieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Ferrara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaia Pellegatta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

